ClinicalTrials.gg
Status unknownNCT05618470Updated Nov 17, 2022

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

A Phase 2/3 interventional study of Wumeiwan Jiawei Fang and botulinum toxin A in Dry Eye Syndromes, Meige Syndrome and Blepharospasm, sponsored by China Academy of Chinese Medical Sciences. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-17.

Sponsored by China Academy of Chinese Medical Sciences · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Jan 2018, registered Oct 2022).
Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.

Read the detailed description

Idiopathic blepharospasm is an idiopathic dysfunction characterized by involuntary spasms of the eyelids bilaterally that interfere with visual function and cause ocular discomfort. The incidence has increased each year in recent years, and the disease may present with persistent eye closure or even functional blindness in advanced stages. In some patients, the disease may be associated with submandibular dystonia, known as Meige's syndrome. Currently, the disease is treated symptomatically. Such as oral.These treatments not only have large side effects, but also make it difficult to relieve the patient of multiple lesions in the eyes, face and tongue. Chinese medicine has unique advantages in treating this disease, highlighting the overall diagnosis and solving different parts of the disease in an integrated manner. Wu Mei Wan is a traditional Chinese medicine prescription, and our team has been using Wu Mei Wan Jia Wei Fang for the treatment of Meige syndrome since 2009 under the leadership of Gao Jiansheng, a famous Chinese medicine teacher in the capital, and found significant therapeutic effects in preliminary clinical observation, but there is a lack of large sample of randomized controlled clinical studies. In this study, we propose to systematically observe the efficacy of traditional Chinese medicine in the treatment of idiopathic blepharospasm by using the traditional sutra formula for idiopathic blepharospasm as a test group and local botulinum toxin A injection as a control group, and to scientifically evaluate the efficacy of the Wu Mei Wan Jia Wei Fang in the treatment of idiopathic blepharospasm.The results were evaluated in order to provide new treatment options for the clinical management of idiopathic blepharospasm (including Meige syndrome) and to benefit more patients.

02

Conditions studied

  • Dry Eye Syndromes
  • Meige Syndrome
  • Blepharospasm
  • Hyperactivity

Keywords

  • Wumeiwan Jiawei Fang
  • Blepharospasm
  • Meige syndrome
03

In context

Dry Eye Syndromes

1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

China Academy of Chinese Medical Sciences is the lead sponsor of 62 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Idiopathic blepharospasm met the diagnostic criteria.
  2. The age ranges from 18 to 80 years.
  3. Liver Yang deficiency,mixed syndrome of cold and heat.
  4. Signed

Exclusion criteria

Exclusion Criteria:

  1. Secondary blepharospasm due to keratoconjunctivitis, trichiasis, and blepharitis.
  2. Open eyelid disuse.
  3. hemifacial spasm.
  4. The patient had undergone eye surgery in the previous 6 months.
  5. Allergic to the ingredients in the medicine.
  6. Corneal lenses were worn during the study.
  7. A woman who is pregnant or breastfeeding.
  8. Combined with cardiovascular, cerebrovascular,Liver and kidney function, hematopoietic system serious primary disease, mental patients, combined with stroke patients.
  9. At the same time, use drugs that interfere with the evaluation of drug efficacy.
  10. Idiopathic blepharospasm is treated with other drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Wumeiwan Jiawei Fang

    This group will take Wumei pill granule orally.

    Drug: Wumeiwan Jiawei Fang

  • Active comparator
    botulinum toxin A

    In this group, Botulinum toxin type A (Lanzhou Biopharmaceutical Co. LTD.) was injected locally around the eye.

    Drug: botulinum toxin A

Interventions

  • DrugWumeiwan Jiawei Fang

    orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.

    Also known as: nothing

  • Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.

    Also known as: nothing

06

What researchers measure

Primary outcomes

  1. The degree of relief of blepharospasm was evaluated by Jankovic Rating Scale.

    According to the Jankovic Rating Scale (JRS), in terms of severity and frequency, the score ranges from 0 to 4, with the highest score being 8. The higher the score is, the more severe the spasm is.

    Time frame: Six months

  2. The Blepharospasm Disability Index (BSDI) was used to evaluate the impact of blepharospasm on daily living activities before and after treatment.

    A total of 6 items were included, including walking, reading, driving, shopping, watching television and general activities. Each item was scored from 0 to 4 points and was self-evaluated by the patients. The total score of BSDI was 24 points.The higher the score is, the more severe the spasm is.

    Time frame: Six months

  3. Traditional Chinese Medicine(TCM) syndrome scale evaluated the change of systemic syndrome before and after treatment.

    The score for each syndrome is the sum of the highest scores obtained for each diagnosis of the syndrome. The full score is 30 points. Efficacy score = (Total score of pre-treatment symptoms➖Total post-treatment symptom score)/Total score of pre-treatment symptoms×100%. Symptoms basically disappear, reducing by 95 to 100 percent; Obvious effect: symptoms decreased significantly, reaching more than 75%; Effective: symptoms decreased to more than 55%; Ineffective: No or slightly reduced symptoms, only less than 50%..

    Time frame: Six months

  4. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    According to whether there are common side effects of botulinum toxin such as ptosis, diplopia, photophobia, dry eye, gastrointestinal tract of exposed keratitis, whether there are gastrointestinal reactions and other side effects that may be related to the Chinese medicine granule preparation in this study.

    Time frame: Six months

  5. According to the Jankovic rating scale, the recurrence was determined at 14 days, 42 days, 3 months and 6 months after medication

    According to the Jankovic rating scale, the recurrence situation at 14 days, 42 days, 3 months and 6 months after medication was determined, and the increase of spasm intensity by 1 grade or more was considered as recurrence.

    Time frame: Six months

  6. Number of participants with treatment-related adverse events as assessed by systemic response, routine blood tests, liver function (ALT), kidney function (BUN, Cr).

    1. Systemic reaction (record at any time); 2. Routine blood tests: the detection points were 14 days, 42 days, 3 months and 6 months after the first visit and treatment; 3. Liver function (ALT), kidney function (BUN, Cr) : The detection points were 14 days, 42 days, three months and six months after the first visit and treatment.

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
  • Eye Hospital, China Academy of Chinese Medical Sciences;GuangAnmen Hospital, China Academy of Chinese Medical Sciences;XiYuan Hospital, China Academy of Chinese Medical Sciences
    Beijing, Beijing 10040, China
    Recruiting
    • Xi Chen · Contact15300307564
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05618470
Lead sponsor
China Academy of Chinese Medical Sciences
Responsible party
Yang Wei (professor, China Academy of Chinese Medical Sciences) — Principal investigator
First posted
Nov 16, 2022
Start date
Jan 12, 2018
Primary completion
Aug 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Nov 17, 2022

Study contacts

wei yang
Contact
506910548@qq.com
18600484803 ext. 010-68686185
wei yang
principal investigator · China Academy of Chinese Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion